Intratumoral CD3+ and NKp46+ Cells in Colorectal Liver Metastases

U

University of Milan

Status

Completed

Conditions

Colorectal Liver Metastases

Treatments

Procedure: Hepatic resection

Study type

Observational

Funder types

Other

Identifiers

NCT02615665
NKTCellsInCLM

Details and patient eligibility

About

The long-term outcome of patients resected for colorectal liver metastases (CLM) after neoadjuvant chemotherapy (CHT) depends by several tumoral and non-tumoral factors, such as the immune response to the tumor and to the CHT. The aim of this study was to investigate the impact of the pathological and immunological response in patients undergoing liver resection for CLM after CHT in regards to the long-term outcome.

Full description

The immunoreactivity to CD3+ and NKp46+ cells inside the tumor, at the border between the tumor and the normal liver, and inside the normal liver will be tested by computer-assisted image analyses in patients undergoing liver resection for CLM between 2005 and 2013 preoperatively treated with oxaliplatin or irinotecan with or without bevacizumab or cetuximab. The survival will be assessed in relation to several prognostic factors and to that immunoreactivity.

Enrollment

121 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • histological proven colorectal liver metastases
  • complete clinical, surgical, pathological and follow-up data

Exclusion criteria

  • non-radical surgery
  • incomplete clinical, surgical, pathological and follow-up data

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems